We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Offers Guidance on Marketing Applications for Transdermal Patches
EMA Offers Guidance on Marketing Applications for Transdermal Patches
October 8, 2012
Manufacturers of transdermal patches should minimize the amount of residual drug substance in the patch as much as possible to avoid patient and environmental safety risks, according to a new European Medicines Agency (EMA) draft guideline.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor